Anavex Life Sciences Corp. (AVXL)
2.47
-0.07
(-2.76%)
USD |
NASDAQ |
Jun 10, 16:00
2.47
0.00 (0.00%)
After-Hours: 18:00
Anavex Life Sciences SG&A Expense (Quarterly) : 2.126M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 2.126M |
| September 30, 2025 | 3.549M |
| June 30, 2025 | 4.50M |
| March 31, 2025 | 2.621M |
| December 31, 2024 | 3.146M |
| September 30, 2024 | 2.781M |
| June 30, 2024 | 2.859M |
| March 31, 2024 | 2.79M |
| December 31, 2023 | 2.609M |
| September 30, 2023 | 2.592M |
| June 30, 2023 | 3.248M |
| March 31, 2023 | 2.883M |
| December 31, 2022 | 3.317M |
| September 30, 2022 | 3.902M |
| June 30, 2022 | 3.186M |
| March 31, 2022 | 2.915M |
| December 31, 2021 | 3.067M |
| September 30, 2021 | 2.879M |
| June 30, 2021 | 2.434M |
| March 31, 2021 | 2.234M |
| December 31, 2020 | 1.471M |
| September 30, 2020 | 1.403M |
| June 30, 2020 | 1.382M |
| March 31, 2020 | 1.720M |
| December 31, 2019 | 1.352M |
| Date | Value |
|---|---|
| September 30, 2019 | 1.635M |
| June 30, 2019 | 1.389M |
| March 31, 2019 | 2.061M |
| December 31, 2018 | 1.761M |
| September 30, 2018 | 1.482M |
| June 30, 2018 | 1.620M |
| March 31, 2018 | 1.489M |
| December 31, 2017 | 1.398M |
| September 30, 2017 | 1.361M |
| June 30, 2017 | 1.405M |
| March 31, 2017 | 1.116M |
| December 31, 2016 | 1.126M |
| September 30, 2016 | 2.244M |
| June 30, 2016 | 1.376M |
| March 31, 2016 | 0.8528M |
| December 31, 2015 | 3.862M |
| September 30, 2015 | 3.220M |
| June 30, 2015 | 0.7135M |
| March 31, 2015 | 0.4512M |
| December 31, 2014 | 0.4521M |
| September 30, 2014 | 0.2953M |
| June 30, 2014 | 0.7338M |
| March 31, 2014 | 0.903M |
| December 31, 2013 | 0.239M |
| September 30, 2013 | 0.3038M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Tenaya Therapeutics, Inc. | 5.447M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Oncolytics Biotech, Inc. | 4.729M |
| Sangamo Therapeutics, Inc. | 6.818M |
| Sarepta Therapeutics, Inc. | 108.95M |